ArticleAAPS PharmSciTech2026
Design and Development of Prolong-acting Intelligent Nano-depot (PaIND) for Improving Patient Adherence.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging encapsulation techniques for controlled and targeted delivery of bioactive compounds in food and nutraceutical systems.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication adherence is a major limitation in the current era. The purpose of the current research was to develop a Prolong-acting intelligent nano-depot (PaIND) for patients diagnosed with hypercholesterolemia, utilizing Rosuvastatin (RSV), to reduce the need for frequent medication administration. PaIND were formulated with poly(lactic-co-glycolic acid 75:25) (PLGA) as the biodegradable polymer, Dimethyl sulfoxide (DMSO) as the solvent, sesame oil as the oil, Span 80 and Tween 80 as the surfactant and co-surfactant, respectively. PaIND was developed systematically by application of quality by design (QbD). A risk assessment approach and Taguchi design were used to screen for significant materials (CMAs) and process attributes (CPPs). PaIND was optimized by applying central composite design (CCD). PaIND was designed and evaluated for prolonged controlled RSV release, gelling time, nano-sized particles, stability, sterility, and other parameters. The chosen excipients showed controlled delivery over a prolonged period, with no signs of burst release. Higher delta values and S/N ratios in the Taguchi design indicate a significant influence of the amount of PLGA, span 80, and tween 80 on the quality of PaIND. Quadratic effect was observed for each CMA on chosen CQAs in CCD. The optimum PaIND showed 86.99% RSV release in 30 days, a 173 nm size, and a 3.6 s gelling time-physical properties aligned with prolonged drug release. Lower PDI and viscosity, negative zeta potential, high transmittance and entrapment efficiency, improved stability and sterility, better use of PaIND. PaIND was successfully designed and developed, integrating recent regulatory compliance requirements. The newer system is highly patient-friendly and ready for commercial use following successful preclinical trials.
Indexed as
Identifiers
41882271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.